Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 337-347

  Humphrey, Stephen J ^a,b   Turman, Chauncey N ^a   Curry, James T ^a   Wheeler, Gracella J ^a  

^a PFIZER INC   (United States)

^b PharmOptima   (United States)

Author keywords

Cardiovascular; Dog; Dopamine agonist; QTc; Trecetilide

Indexed keywords

ANTIARRHYTHMIC AGENT; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; IBUTILIDE FUMARATE; IMIDAZOQUINOLINE DERIVATIVE; PNU 108342E; PNU 142774E; POTASSIUM CHANNEL HERG; ROPINIROLE; SUMANIROLE; TRECETILIDE; UNCLASSIFIED DRUG; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; PNU-142774E; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; GENETIC TRANSFECTION; HEART RATE; IN VITRO STUDY; MEAN ARTERIAL PRESSURE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TACHYCARDIA; VOMITING; ACTION POTENTIAL; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG POTENTIATION; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; APOMORPHINE; BLOOD PRESSURE; DOGS; DOPAMINE AGONISTS; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; IMIDAZOLES; INDOLES; QUINOLINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 33745727528     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000205983.05771.f5     Document Type: Article

References (64)

1. de Paulis T. Sumanirole pharmacia. Curr Opin Investig Drugs. 2003;4:77-82.
2. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs. 2004;5:720-726.
3. DiChiara G, Gessa GL. Pharmacology and neurochemistry of apomorphine. Adv Pharmacol Chemother. 1978;15:87-160.
4. Eden RJ, Costall B, Domeney AM, et al. Preclinical pharmacology of ropinirole (SK&F 101468-A), a novel dopamine D2 agonist. Pharmacol Biochem Behav. 1991;38:147-154.
5. Tulloch IF. Pharmacologic profile of ropinirole: a non-ergoline dopamine agonist. Neurology. 1997;49(Suppl 1):S58-S62.
6. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm. 1999;56:217-224.
7. Ahnve S. Is QT interval prolongation a strong or weak predictor for cardiac death? Circulation. 1991;84:1862-1865.
8. Drici M-D, Barhanin J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie. 2000;55:185-193.
9. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003;58:32-45.
10. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
11. Naccarelli GV, Dougherty AH, Nappi J, et al. Pharmacological therapy of arrhythmias. In: Cardiac Arrhythmias: A Practical Approach. Mount Kisco: Futura Publishing; 1991:413-485.
12. Opie LH. Electricity out of control: ventricular arrhythmias. In: The Heart. Physiology and Metabolism. 2nd edn. New York: Raven Press; 1991:484-501.
13. Stratmann HR, Kennedy HL. Torsades des pointes associated with drugs and toxins: recognition and management. Am Heart J. 1987;113:1470-1482.
14. Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis. 1988;31:115-172.
15. Schoeten EG, Dekker JM, Meppelink P, et al. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation. 1991;84:1516-1523.
16. Pourrias B, Porsolt RD, Lacroix P. QT interval prolongation by noncardiovascular drugs: a proposed assessment strategy. Drug Dev Res. 1999;47:55-62.
17. Yang T, Snyders D, Roden DM. Drug block of IKr: model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol. 2001;38:737-744.
18. Davie C, Pierre-Valentin J, Pollard C, et al. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (IKr) channel. J Cardiovasc Electrophysiol. 2004;15:1302-1309.
19. Gintant GA, Limberis JT, McDermott JS, et al. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol. 2001;37:607-618.
20. Kongsamut S, Kang J, Chen XL, et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol. 2002;450:37-41.
21. Rutherford-Root KL, Lawson JA, Clark MA, et al. Dopamine receptor agonists used for the treatment of Parkinson's disease differentially influence hERG potassium channel function and cardiac action potential duration. Soc Neurosci. 2002:194:4.
22. Hurst RS, Higdon NR, Lawson JA, et al. Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol. 2003;482:31-37.
23. Mathias CJ. Cardiovascular autonomic dysfunction in Parkinsonian patients. Clin Neurosci. 1998;5:153-166.
24. Mitchelson F. Pharmacological agents affecting emesis: a review (Part I). Drugs. 1992a;43:295-315.
25. Mitchelson F. Pharmacological agents affecting emesis: a review (Part II). Drugs. 1992b;43:443-463.
26. Buchanan LV, LeMay RJ, Walters RR, et al. Antiarrhythmic and electrophysiological effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model. J Cardiovasc Electrophys. 1996;7:113-119.
27. Hester JB, Gibson KJ, Buchanan LV, et al. Progress toward the development of a safe and effective agent for treating reentrant cardiac arrhythmias: synthesis and evaluation of ibutilide analogs with enhanced metabolic stability and diminished proarrhythmic potential. J Med Chem. 2002;44:1099-1115.
28. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy of Sciences; 1996:56-70.
29. Humphrey SJ. Cardiovascular effects of nicorandil and nitroprusside in furosemide plus digoxin pretreated dogs. Drug Dev Res. 1994;32:172-182.
30. Humphrey SJ, Smith MP, Brown WP, et al. Cardiovascular and pharmacokinetic interactions between acute tirilazad mesylate and chronic nimodipine in conscious dogs. Drug Dev Res. 1993;28:141-152.
31. Humphrey SJ, Smith MP, Hsu CL, et al. Cardiovascular effects of the R- and S-enantiomers of ibutilide in conscious beagle dogs. Meth Find Exp Clin Pharmacol. 2001;23:449-455.
32. Lansing PF. Maine Med Assoc. 1962;July:166.
33. Van de Water A, Vehehyeu J, Xhonneux R, et al. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Meth. 1989;22:207-217.
34. Sager PT. New advances in class III antiarrhythmic drug therapy. Curr Opin Cardiol. 2000;15:41-53.
35. Swagzdis JE, Wittendorf RW, DeMarinus RM, et al. Pharmacokinetics of dopamine-2 agonists in rats and dogs. J Pharm Sci. 1986;75:925-928.
36. Reavill C, Boyfield I, Coldwell M, et al. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rat. J Pharm Pharmacol. 2000;52:1129-1135.
37. Humphrey SJ, Zins GR. Whole body and regional hemodynamic effects of minoxidil in the conscious dog. J Cardiovasc Pharmacol. 1984;6:979-988.
38. Humphrey SJ, Schwende FJ. Comparative cardiovascular interactions characterizing the vasodilator action of nicorandil in conscious beagle dogs. J Cardiovasc Pharmacol. 1995;26:810-821.
39. Humphrey SJ. Cardiovascular and pharmacokinetic drug interactions between nicorandil and propranolol, atenolol, or diltiazem in conscious dogs. Meth Find Exp Clin Pharmacol. 1998;20:779-791.
40. Spence S, Soper K, Hoe C-M, et al. The heart rate-corrected QT interval of conscious beagle dogs: a formula based on analysis of covariance. Toxicol Sci. 1998;45:247-258.
41. Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993;329:1021-1027.
42. Martin WR, Wieler M. Treatment of Parkinson's disease. Can J Neurol Sci. 2003;30(Suppl 1):S27-S33.
43. Zareba W, Lin DA. Antipsychotic drugs and QT interval prolongation. Psychiatr Q. 2003;74:291-306.
44. van Laar T, van der Geest R, Danhof M, et al. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin Neuropharmacol. 1998;21:152-158.
45. Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27:907-914.
46. Walters AS, Ondo WG, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord. 2004;19:1414-1423.
47. Coldwell MC, Boyfield I, Brown T, et al. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3, and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1999;127:1696-1702.
48. Millan MJ, Cussac D, Gobert A, et al. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther. 2004;309:903-920.
49. Durif F, Paire M, Deffond D, et al. Relation between clinical efficacy and pharmacokinetics after sublingual apomorphine in Parkinson's disease. Clin Neuropharmacol. 1993;16:157-166.
50. Przedborski S, Levivier M, Raftopoulos C, et al. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Mov Disord. 1995;10:28-36.
51. van Laar T, Jansen EN, Neef C, et al. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord. 1995;10:433-439.
52. Thalamas C, Taylor A, Brefel-Courbon C, et al. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Eur J Clin Pharmacol. 1999;56:299-303.
53. Taylor AC, Beerahee A, Citerone DR, et al. Lack of pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. Pharmacotherapy. 1999;19:150-156.
54. EMEA (European Agency for the Evaluation of Medicinal Products). ICH S7B - Note for guidance on safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. London, UK: 21 February 2002.
55. Ramanathan KB, Bodenheimer MM, Banka VS, et al. Contrasting effects of dopamine and isoproterenol in experimental myocardial infarction. Am J Cardiol. 1977;39:413-417.
56. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001:411-420.
57. Malik M. The imprecisions in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol. 2002;25:209-216.
58. Edvinsson L, Hardebo JE, McCulloch J, et al. Effects of dopamine agonists and antagonists on isolated cerebral blood vessels. Acta Physiol Scand. 1978;104:349-359.
59. Brodde OE. Vascular dopamine receptors: demonstration and characterization by in vitro studies. Life Sci. 1982;26:289-306.
60. Goldberg LI, Rajfer SI. Dopamine receptors: applications in clinical cardiology. Circulation. 1985;72:245-248.
61. Luchsinger A, Velasco M, Urbina A, et al. Comparative effects of dopaminergic agonists on cardiovascular, renal, and renin-angiotensin systems in hypertensive patients. J Clin Pharmacol. 1992;32:55-60.
62. 2 receptor activation in the canine cardiac sympathetic ganglia. J Pharmacol Exp Ther. 1996;279:822-829.
63. Semeraro C, Ferrini R, Allievi L, et al. Peripheral vascular and neuronal effects of dopamine receptor agonists. A comparison with receptor binding studies in rat striatum. Naunyn Schmiedebergs Arch Pharmacol. 1990;342:539-546.
64. Smith RV, Velagapudi RB, McLean AM, et al. Interactions of apomorphine with serum and tissue proteins. J Med Chem. 1985;28:613-620.